Source-grounded facts extracted from Keros Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Keros Therapeutics, Inc. shareholders approved Advisory vote on executive compensation. at the 2026-06-03 meeting.
“The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3. The votes cast were as follows: Votes For Votes Against Votes Abstain Broker Non-Votes 14,273,625.27 974,049 2,038 2,243,514”
Keros Therapeutics, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
“The Company’s stockholders approved Proposal 2. The votes cast were as follows: Votes For Votes Against Votes Abstain 16,708,279.27 783,953 994 There were no broker non-votes with respect to Proposal 2.”
Keros Therapeutics, Inc. shareholders approved Election of two nominees for director to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. at the 2026-06-03 meeting.
“The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jean-Jacques Bienaimé 10,093,559.27 5,156,153 2,243,514 Charles Newton 14,716,598 533,114 2,243,514”
Keros Therapeutics, Inc. reported quarter ended March 31, 2026 results: net income $23.7 million.
“Keros reported a net loss of $23.7 million in the first quarter of 2026”
Keros Therapeutics, Inc. reported the year ended December 31, 2025 results: net income net income of $87.0 million.
“Keros reported a net loss of $23.5 million for the fourth quarter and net income of $87.0 million for the year ended December 31, 2025”
Keros Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income net loss of $23.5 million.
“Keros reported a net loss of $23.5 million for the fourth quarter”
Keros Therapeutics, Inc. announced a restructuring with charges of approximately $3.2 million (approximately 45%).
“These plans were communicated to affected employees on May 29, 2025. The Company expects to incur one-time cash charges associated with the Reorganization of approximately $3.2 million related to employee severance payments and related costs, which are expected to be expensed in the second quarter of 2025. In addition, the Company has committed to pay one-time”
Keros Therapeutics, Inc.: Certificate of Designations establishing Preferred Shares filed with Delaware Secretary of State (effective 2025-04-09).
“the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on April 9, 2025.”
Keros Therapeutics, Inc.: Amended and Restated Bylaws to update advance notice provisions for director nominations, enhance disclosure requirements, clarify stockholder meeting procedures, and make conforming edits (effective 2025-03-05).
“On March 5, 2025, in connection with a periodic review of corporate governance matters, the board of directors (the “Board”) of Keros Therapeutics, Inc. (the “Company”) approved and adopted the Amended and Restated Bylaws of the Company (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.”
Jean-Jacques Bienaimé was appointed as Lead Independent Director at Keros Therapeutics, Inc..
“the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.”
Carl L. Gordon resigned as Chair of the Board at Keros Therapeutics, Inc..
“Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.”
Christopher Rovaldi was appointed as President and Chief Operating Officer at Keros Therapeutics, Inc..
“The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.”
Keros Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income net loss of $43.1 million.
“Keros reported a net loss of $43.1 million in the first quarter of 2024 as compared to a net loss of $35.8 million in the first quarter of 2023.”
Simon Cooper resigned as Chief Medical Officer at Keros Therapeutics, Inc..
“On February 29, 2024, Simon Cooper, M.B.B.S., resigned from his position as Chief Medical Officer of Keros Therapeutics, Inc. (the “Company”), effective March 12, 2024, to pursue other opportunities.”
Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.2 million for the year ended December 31, 2023, net income a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023.
“Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.”
Keros Therapeutics, Inc. reported for the quarter ended September 30, 2023 results: net income net loss of $39.4 million.
“Keros reported a net loss of $39.4 million in the third quarter of 2023 as compared to a net loss of $23.5 million in the third quarter of 2022.”
Keros Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income a net loss of $37.5 million.
“Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended June 30, 2023.”
Keros Therapeutics, Inc. shareholders approved Ratification of the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
“Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2023 The Company’s stockholders approved Proposal 2. The votes cast were as follows: Votes For Votes Against Votes Abstain 26,790,800 2,224 1 There were no broker non-votes with respect to Proposal 2.”
Keros Therapeutics, Inc. shareholders approved Election of two nominees for director to hold office until the Company’s 2026 Annual Meeting of Stockholders at the 2023-06-06 meeting.
“Proposal 1 – Election of Directors The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Carl L. Gordon 11,486,998 13,409,802 1,896,225 Tomer Kariv 19,234,712 5,662,088 1,896,225”
Keros Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $35.8 million.
“Keros reported a net loss of $35.8 million in the first quarter of 2023 as compared to a net loss of $24.2 million in the first quarter of 2022.”
Dr. Alpna Seth was appointed as director at Keros Therapeutics, Inc..
“Dr. Alpna Seth as a director of the Company, effective on May 1, 2023.”
Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022.
“Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter and year ended December 31, 2022.”
Keros Therapeutics, Inc. amended Lease Amendment with Revolution Labs Owner, LLC (effective 2023-01-06).
“On January 6, 2023, Keros Therapeutics, Inc. (the “Company”) entered into a first amendment (the “Lease Amendment”) to that certain indenture of lease, dated September 7, 2021 (as amended, the “Lease”) with Revolution Labs Owner, LLC, a Delaware limited liability company (the “Landlord”), with respect to the Company’s office and laboratory space consisting of approximately 35,662 square feet located at 1050 Waltham Street, Lexington, Massachusetts (the “Premises”).”
Keros Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $23.5 million.
“Keros reported a net loss of $23.5 million in the third quarter of 2022 as compared to a net loss of $20.3 million in the third quarter of 2021.”
Jennifer Lachey changed role as Senior Vice President of Discovery at Keros Therapeutics, Inc..
“She remains employed by the Company and her title has been changed from Chief Scientific Officer to Senior Vice President of Discovery.”
Christopher Rovaldi was appointed as Chief Operating Officer at Keros Therapeutics, Inc..
“Christopher Rovaldi has been appointed to serve as the Company’s Chief Operating Officer, effective as of February 1, 2022.”
Simon Cooper was appointed as Chief Medical Officer at Keros Therapeutics, Inc..
“Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021”
Claudia Ordonez departed as Chief Medical Officer at Keros Therapeutics, Inc..
“Dr. Cooper is succeeding Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.